A phase 2 trial showed that olaparib plus radium 223 prolonged progression-free survival in a subset of patients with castration-resistant prostate cancer and bone metastases. Radiographic progression ...

Telmisartan, an FDA-approved blood pressure drug, could boost a certain cancer treatment's effectiveness against tumors, a ...

Assessment of PSMA PET/CT derived predictive markers for 177Lu-PSMA-617 treatment outcomes: Results from the U.S. Expanded-Access program. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found ...

Investigation of the PORTOS gene expression signature and the benefit of docetaxel in the ECOG-ACRIN E3805 CHAARTED randomized trial. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary ...

Scientists at Dartmouth Cancer Center have discovered that a common drug used to treat high blood pressure may also help fight cancer more effectively. The study, published in The Journal for ...

The median OS was 28 months with abiraterone-prednisone, 37 months with olaparib alone, and 68 months with abiraterone-prednisone-olaparib. In patients with metastatic castration-resistant prostate ...

High blood pressure is strongly correlated to cancer. This risk factor, among others including smoking, obesity, and ...